bioMerieux SA

As of June 30, 2026, bioMerieux SA carries a market capitalization of 8.06B, placing it among publicly traded companies globally. Its enterprise value stands at 7.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

bioMerieux SA's next confirmed earnings release is scheduled for March 4, 2027.

As of June 30, 2026, bioMerieux SA has 117.69M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, bioMerieux SA maintains a current ratio of 2.30, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, bioMerieux SA's stock has declined approximately 22.26% over the past 52 weeks. The 50-day moving average sits at 77.14, while the 200-day moving average is 81.54.

As of June 30, 2026, bioMerieux SA holds 657.70M in cash and equivalents against 421.80M in total debt, resulting in a net debt position of -390.70M. Total book value stands at 4.30B, with working capital of 1.47B providing operational flexibility.

bioMerieux SA's most recent stock split took place on September 20, 2017 with a 1:3 split ratio.